2025-06-16-Jefferies-幻灯片_肥胖症相关公司在ADA会议及下半年的布局_安进_诺和诺德等_79页_7mb

报告摘要

Biotech Obesity Report Summary

Overview:
Improving biotech sentiment in obesity therapeutics, driven by ongoing ADA evaluations and data setups for key players. Market focuses on Catalysts like AMGN and formulations. Biotech reports cover AMGN, NVO, GPCR, SRRK.

Key Highlights:

Sentiment improving due to MFN/tariff relief and stronger LLY performance.
Lead obesity names: AMGN, NVO, GPCR, SRRK, VKTX, ZEAL.
H2 catalysts include ADA data presentations (June 18), investor events, and Phase II/III updates.

AMGN:

Cautious optimism on ADA Phase II data (6/23), demonstrating higher efficacy (18-20% weight loss), but bearish investor sentiment due to 40-50% GI events despite "new titration."
Potential to "climb the wall of worry" if data supports, with Phase III LP(a) focus in 2026.

NVO:

Incremental obesity updates; H7 dose Wegovy shows +3% weight loss vs. standard, with label expansion filing anticipated. However, overshadowed by Lilly's amylin Phase I data.
Market focus on US GLP-1 volume trends and CVS formulary driving NovoCare litigation visibility.

GPCR:

Orf GLP-1 oral Phase II data positive with proof-of-concept efficacy (7-8% weight loss) and improved GI tolerability under "start low go slow" strategy, differentiating from peers.

SRRK/VKTX/ZEAL:

SRRK: Mixed myostatin data; expects ~50% lean mass preservation but safety concerns.
VKTX: SubQ VK2735 (GLP-1/GIP peptide) shows ~13% weight loss, high tolerance with low AE rates. Oral formulation pending Ph2 data.
ZEAL: Amylin preclinical and Phase I data support ~8-11% weight loss with tolerable GI events; Synectholintide Phase IIb set to report.

Catalysts:

ADA (June 18): AMGN, NVO, GPCR presentations.
Upcoming: AMGN Phase II full data, LLY/LY amylin Phase II HTE, GCpike NVO data, VKTX oral Phase II.

Risks:

Biosimilars (e.g., d-mab) could impact AMGN; orfo competition, SRRK capitalization issues, GVOL tolerability concerns.
Asian player competition could pressure late-stage oral GLP-1s.

展开完整摘要